Upstream Bio shares rise after phase 2 severe asthma primary endpoint
Upstream Bio shares rose after its severe asthma treatment met the primary endpoint in a phase 2 trial. The stock gained 9.3% to $6.57 in premarket trading; it was down 78% year to date at market close.